Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Generalized anxiety disorder
Economic burden and healthcare resource utilization
12 evidence topics · 12 sources
Direct and indirect costs: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use, adjusted: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded
Work productivity and activity impairment: 2022 US National Health and Wellness Survey, sponsor-funded
Healthcare resource use with and without co-occurring major depressive disorder: U.S. claims 2022 to 2024, sponsor-authored
U.S. health care spending on anxiety disorders, 2016
| Measure | Anxiety disorders |
|---|---|
| Spending rank among 154 health conditions | “21”View highlighted excerpt for this quote |
| Health care spending, 2016 $Billion (95% CI) | “42.4 (37.8-47.7)”View highlighted excerpt for this quote |
| Age 20 to 64 years, % of spending | “75.3”View highlighted excerpt for this quote |
| Public insurance, % of spending | “49.6”View highlighted excerpt for this quote |
| Private insurance, % of spending | “41.2”View highlighted excerpt for this quote |
| Out-of-pocket payments, % of spending | “9.2”View highlighted excerpt for this quote |
| Ambulatory care, % of spending | “55.7”View highlighted excerpt for this quote |
| Inpatient care, % of spending | “7.0”View highlighted excerpt for this quote |
| Prescribed pharmaceuticals, % of spending | “21.3”View highlighted excerpt for this quote |
Incremental direct medical expenditures for anxiety disorders: Medical Expenditure Panel Survey 2009 and 2010
“Data from the 2009 and 2010 Medical Expenditure Panel Survey (MEPS) were used to estimate the annual incremental healthcare expenditures associated with anxiety disorders, for the ambulatory adult population of the U.S.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual overall healthcare expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient visits, prescription medications, and office-based visits together accounted for almost 93% of the overall cost.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the prevalence of self-reported anxiety disorders in MEPS, their total direct medical expenditure is estimated at approximately $33.71 billion in 2013 US dollars” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs for anxiety disorders by insurance type: Medical Expenditure Panel Survey 2011 to 2014
“Using weighted nationally representative data from the 2011-2014 Medical Expenditure Panel Surveys, total OOP health care costs were assessed for all respondents who indicated that they had an anxiety disorder (N = 9985).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average annual OOP costs among individuals with anxiety was $1152.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The highest OOP cost were incurred by individuals with private fee-for-service (FFS) insurance ($1356/year, 4.1% of annual income), while individuals enrolled in HMOs with dual Medicare/Medicaid had the lowest OOP cost ($129/year, 6.8% of annual income).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals without insurance had high OOP cost burden ($1309/year, 12.5% of annual income).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs before and after starting pharmacotherapy for GAD: U.S. claims 2003 to 2007
“Using a large US health insurance database, we identified all patients with evidence of GAD (ICD-9-CM diagnosis code 300.02) who initiated pharmacotherapy with medications commonly used to treat GAD (eg, selective serotonin reuptake inhibitors [SSRIs], venlafaxine, benzodiazepines) between 1/1/2003 and 12/31/2007.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 10,275 patients met all study inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) total healthcare costs increased from $4812 ($10,006) during pretreatment to $7182 ($22,041) during follow-up (p < 0.01); costs of GAD-related pharmacotherapy during follow-up were $420 ($485).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medical costs of GAD in primary care: systematic review
“GAD patients had significantly higher median medical costs than primary care patients without GAD (US $2375 versus $1448).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean annual medical cost of GAD was $2138 higher than for other anxiety disorders (mean $6475).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GAD is associated with significant burden on patient functioning and well-being, leading to increased health care utilization and medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-of-illness studies of anxiety disorders: systematic review and meta-analysis
“We identified 13 top-down and 11 bottom-up COI studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In top-down COI studies, direct costs of AD, on average, corresponded to 2.08% of health care costs and 0.22% of GDP, whereas indirect costs, on average, corresponded to 0.23% of GDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis revealed an increase in direct costs by 1.60 (1.16-2.22; p = 0.005) for SAD and 2.60 (2.01-3.36; p < 0.001) for GAD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost of anxiety disorders in the United States, 1990
“We estimated the annual cost of anxiety disorders to be approximately $42.3 billion in 1990 in the United States, or $1542 per sufferer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the $256 in workplace costs per anxious worker, 88% is attributable to lost productivity while at work as opposed to absenteeism.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote